Wall Street brokerages expect that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will report sales of $75.70 million for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have provided estimates for Neurocrine Biosciences’ earnings, with the lowest sales estimate coming in at $57.00 million and the highest estimate coming in at $84.60 million. The firm is scheduled to report its next quarterly earnings results on Tuesday, February 13th.
According to Zacks, analysts expect that Neurocrine Biosciences will report full year sales of $75.70 million for the current year, with estimates ranging from $65.10 million to $151.67 million. For the next year, analysts forecast that the firm will report sales of $313.38 million per share, with estimates ranging from $196.30 million to $511.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.36. The business had revenue of $60.77 million during the quarter, compared to analysts’ expectations of $29.38 million. During the same period last year, the company earned ($0.43) earnings per share.
A number of brokerages recently issued reports on NBIX. BMO Capital Markets increased their price target on shares of Neurocrine Biosciences from $75.00 to $84.00 and gave the stock an “outperform” rating in a report on Friday, August 4th. Oppenheimer Holdings, Inc. increased their price target on shares of Neurocrine Biosciences from $70.00 to $85.00 and gave the stock an “outperform” rating in a report on Thursday, November 2nd. Piper Jaffray Companies set a $68.00 price target on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a report on Thursday, August 24th. Citigroup Inc. reissued a “buy” rating and set a $79.00 price target on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Finally, Needham & Company LLC reissued a “buy” rating and set a $86.00 price target on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $78.88.
Shares of Neurocrine Biosciences (NASDAQ:NBIX) opened at $75.46 on Monday. Neurocrine Biosciences has a twelve month low of $37.35 and a twelve month high of $75.98. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37.
In other Neurocrine Biosciences news, insider Haig P. Bozigian sold 26,250 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $1,575,000.00. Following the completion of the sale, the insider now directly owns 144,601 shares in the company, valued at $8,676,060. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Christopher Flint Obrien sold 52,817 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $57.50, for a total transaction of $3,036,977.50. Following the sale, the insider now owns 101,790 shares of the company’s stock, valued at $5,852,925. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 110,810 shares of company stock valued at $6,797,998. 4.80% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the business. Wells Fargo & Company MN increased its position in shares of Neurocrine Biosciences by 14.5% during the third quarter. Wells Fargo & Company MN now owns 945,368 shares of the company’s stock valued at $57,931,000 after acquiring an additional 119,383 shares during the last quarter. Schroder Investment Management Group increased its position in shares of Neurocrine Biosciences by 81.0% during the third quarter. Schroder Investment Management Group now owns 37,105 shares of the company’s stock valued at $2,204,000 after acquiring an additional 16,609 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of Neurocrine Biosciences during the third quarter valued at about $246,000. Legal & General Group Plc increased its position in shares of Neurocrine Biosciences by 14.6% during the third quarter. Legal & General Group Plc now owns 36,497 shares of the company’s stock valued at $2,237,000 after acquiring an additional 4,638 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Neurocrine Biosciences during the third quarter valued at about $1,457,000.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.